Abstract | INTRODUCTION: METHODS: RESULTS: In total, 609 patient admissions met criteria. The mean age was 46±14 years; 81.1% were female. Median pain rating decreased from baseline of 7.0 (5.0-8.0) to 1.0 (0.0-3.0) at end of hospitalization (p<0.001); 87.8% of patients were acute responders. Average pain (N=261) remained below baseline at office visit 1 (5.5 (4.0-7.0); p<0.001). Forty-three percent of patients were sustained responders at 1 month. Headache days (N=266) decreased from 26.8±3.9 at baseline to 22.5±8.3 at the post-discharge office visit (p<0.001). Nausea and vomiting were the most common adverse drug effects and all were mild. CONCLUSION:
Lidocaine infusions may be associated with short-term and medium-term pain relief in refractory chronic migraine. Prospective studies should confirm these results.
|
Authors | Eric S Schwenk, Aaron Walter, Marc C Torjman, Sarah Mukhtar, Harsh T Patel, Bryan Nardone, George Sun, Bhavana Thota, Clinton G Lauritsen, Stephen D Silberstein |
Journal | Regional anesthesia and pain medicine
(Reg Anesth Pain Med)
Vol. 47
Issue 7
Pg. 408-413
(07 2022)
ISSN: 1532-8651 [Electronic] England |
PMID | 35609890
(Publication Type: Journal Article)
|
Copyright | © American Society of Regional Anesthesia & Pain Medicine 2022. No commercial re-use. See rights and permissions. Published by BMJ. |
Chemical References |
|
Topics |
- Adult
- Aftercare
- Female
- Headache
(chemically induced)
- Humans
- Infusions, Intravenous
- Lidocaine
(adverse effects)
- Male
- Middle Aged
- Migraine Disorders
(diagnosis, drug therapy)
- Patient Discharge
- Prospective Studies
- Quality of Life
- Retrospective Studies
- Treatment Outcome
|